Our invention won the Gold Medal at the International Invention Exhibition „Concours Lépine 2013” in Paris organized by „Association des inventeurs et Fabricants Français”
• WO 2014088435 A1for dendrimer PPI-G4-OS-Mal-III,
• WO 2014088434 A1 for dendrimer PPI-G4-DS-Mal-III,
concerning the application of maltotriose-coated 4th generation polypropyleneimine dendrimers for treating neoplastic proliferative diseases, particularly chronic lymphocytic leukemia (CLL).
The Management Board consists of qualified biotechnologists with over 10 years of experience in medical and genetic diagnostics along with a number of years of managerial experience. Founded in June 2015 as a university spin-off, GeneaMed was secured in private financing by INNOventure Fund from Poland. The main stakeholders are the Technology Accelerator the Foundation of the University of Lodz and the INNOventure Investment Fund from Poland.